Key result
Apixaban demonstrates superior efficacy in reducing stroke, systemic embolism, and bleeding events compared to warfarin, and superior stroke reduction without excess bleeding compared to aspirin.
Why the study?
Does apixaban reduce stroke and systemic embolism compared to aspirin or warfarin in patients with atrial fibrillation?
Does apixaban reduce stroke and systemic embolism compared to aspirin or warfarin in patients with atrial fibrillation?
Apixaban is an effective and safe alternative to warfarin and aspirin for stroke prevention in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports apixaban preference in AF; leaves open need for updated comparisons versus newer agents.
Atrial fibrillation is a common arrhythmia that increases the risk of stroke and systemic embolism. Warfarin is a highly effective treatment in reducing this risk, but a narrow therapeutic range, drug and food interactions, required monitoring, and bleeding limit its use. We review Apixaban, an oral inhibitor of Factor Xa, which has been shown in large randomized trials to have superior efficacy in stroke reduction without an excess in bleeding events when compared with aspirin in those deemed unsuitable to receive warfarin, and demonstrates superior efficacy in reducing stroke and systemic embolism in addition to a reduction in bleeding events when compared to warfarin.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2012) conducted a review in Atrial fibrillation. Apixaban vs. Aspirin or Warfarin was evaluated on Stroke and systemic embolism; bleeding events. Apixaban demonstrates superior efficacy in reducing stroke, systemic embolism, and bleeding events compared to warfarin, and superior stroke reduction without excess bleeding compared to aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: